Compare Johnson & Johnson with Similar Stocks
Dashboard
1
High Management Efficiency with a high ROCE of 432,803.06%
2
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.26 times
3
Poor long term growth as Operating profit has grown by an annual rate 0.96% of over the last 5 years
4
Flat results in Jun 25
5
With ROCE of 23.24%, it has a very attractive valuation with a 5.05 Enterprise value to Capital Employed
6
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
USD 515,810 Million (Large Cap)
23.00
NA
2.56%
0.41
25.10%
6.57
Revenue and Profits:
Net Sales:
23,741 Million
(Quarterly Results - Jun 2025)
Net Profit:
5,537 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
30.12%
0%
30.12%
6 Months
46.22%
0%
46.22%
1 Year
48.31%
0%
48.31%
2 Years
36.37%
0%
36.37%
3 Years
26.46%
0%
26.46%
4 Years
30.6%
0%
30.6%
5 Years
47.64%
0%
47.64%
Johnson & Johnson for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.39%
EBIT Growth (5y)
0.96%
EBIT to Interest (avg)
24.32
Debt to EBITDA (avg)
0.26
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.81
Tax Ratio
17.14%
Dividend Payout Ratio
84.80%
Pledged Shares
0
Institutional Holding
74.50%
ROCE (avg)
432,803.06%
ROE (avg)
387,416.25%
Valuation key factors
Factor
Value
P/E Ratio
23
Industry P/E
Price to Book Value
5.74
EV to EBIT
21.71
EV to EBITDA
16.16
EV to Capital Employed
5.05
EV to Sales
5.17
PEG Ratio
NA
Dividend Yield
2.91%
ROCE (Latest)
23.24%
ROE (Latest)
25.13%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Bullish
OBV
No Trend
No Trend
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 304 Schemes (25.69%)
Foreign Institutions
Held by 709 Foreign Institutions (16.9%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
23,741.00
21,894.00
8.44%
Operating Profit (PBDIT) excl Other Income
8,782.00
8,069.00
8.84%
Interest
432.00
287.00
50.52%
Exceptional Items
-450.00
6,820.00
-106.60%
Consolidate Net Profit
5,537.00
10,999.00
-49.66%
Operating Profit Margin (Excl OI)
288.10%
287.60%
0.05%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 8.44% vs -2.78% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -49.66% vs 220.58% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
88,819.00
85,152.00
4.31%
Operating Profit (PBDIT) excl Other Income
28,162.00
29,648.00
-5.01%
Interest
1,150.00
1,177.00
-2.29%
Exceptional Items
-6,241.80
-9,309.30
32.95%
Consolidate Net Profit
14,066.00
13,326.00
5.55%
Operating Profit Margin (Excl OI)
234.40%
260.30%
-2.59%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 4.31% vs 6.36% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 5.55% vs -18.59% in Dec 2023
About Johnson & Johnson 
Johnson & Johnson
Pharmaceuticals & Biotechnology
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.
Company Coordinates 
Company Details
1 Johnson And Johnson Plz , NEW BRUNSWICK NJ : 08933-0001
Registrar Details






